Latest news

Posts about investor

CEO Michael Heltzen at the Beryl Elite's 'AI in Life Sciences' panel

Beryl Elites: AI's Billion-dollar Bet on Life Sciences - From Drug Discovery to Patient Impact (panel)

100× scale-up of NCT production achieved

eXoZymes achieves 100× scale-up of NCT production using exozymes, demonstrating near-perfect feedstock conversion

LA Weekly: The Enzyme Frontier: eXoZymes Unlocks a New Era for Cannabinoid Nutraceuticals and Pharma

LA Weekly: The Enzyme Frontier - eXoZymes Unlocks a New Era for Cannabinoid Nutraceuticals and Pharma

Slack Capital report

Slack Capital report: EXOZ is a once-in-a-lifetime opportunity

'The Upside' interview: Michael Heltzen & Lou Basenese

'The Upside' interview: Michael Heltzen & Lou Basenese

Transcript: EXOZ Q3 2025 update

EXOZ 2025 Q3 Update

eXoZymes provides third quarter 2025 update at 5PM EST today

CSO Tyler Korman - and Chief of Staff, Amy Lunzer

eXoZymes announces cell-free biomanufacturing pioneer, Tyler Korman, as CSO & Amy Lunzer as Chief of Staff

CSO, Tyler Korman

Co-founder of eXoZymes and cell-free biomanufacturing pioneer, Tyler Korman, speaks to his new role as CSO

CEO, Michael Heltzen is interviewed by Jane King

Jane King interviews CEO, Michael Heltzen, in New York